S&P Futures
6,011.50 +24.50 (+0.41%) Dow Futures
44,623.00 +228.00 (+0.51%) Nasdaq Futures
20,945.75 +96.00 (+0.46%) Russell 2000 Futures
2,437.30 +23.70 (+0.98%) Crude Oil
71.26 +0.02 (+0.03%) Gold
2,718.50 +6.30 (+0.23%)
ABIVAX Société Anonyme (AAVXF)
| Previous Close | 0.00 |
| Open | 15.00 |
| Bid | 8.44 x 42300 |
| Ask | 9.21 x 40700 |
| Day's Range | 15.15 - 15.15 |
| 52 Week Range | 10.19 - 15.15 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 695.241M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.70 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAbivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allow
- GlobeNewswire
Abivax presents third quarter 2024 key financial information
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30,
